Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07571174 | A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | PHASE1 | NOT YET_RECRUITING | 32 | — | — | May 1, 2026 | Jun 1, 2029 | May 13, 2026 | 3 | Belgium, Canada |
| NCT07571200 | A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | NOT YET_RECRUITING | 32 | — | — | May 1, 2026 | Jun 1, 2029 | May 6, 2026 | 3 | Belgium, Canada |
| Arm | Type | Description |
|---|---|---|
| LY4256984 | EXPERIMENTAL | LY4256984 administered intrathecally (IT) |
| Name | Type | Description |
|---|---|---|
| LY4256984 | DRUG | Administered IT |
Participants must meet eligibility criteria in the \[L0U-MC-OLMP\] screening protocol before entry into the treatment study. Inclusion Criteria: * Have completed the main treatment period/phase as well as any off-treatment period/phase of Study OWAA, the parent study for this ISA. Exclusion Crite...